Laboratory data of patients with TTP
| Variable . | Normal range . | Recurrent . | Familial . | ||
|---|---|---|---|---|---|
| Acute (n = 9) . | Remission (n = 13) . | Acute (n = 3) . | Remission (n = 4) . | ||
| Platelets, × 1000/μL | |||||
| Average | 29 | 232 | 38 | 253 | |
| (range) | (150 -400) | (10-71) | (178-399) | (9-34) | (191-352) |
| Hemoglobin, g/dL | |||||
| Average | 9.3 | 13.2 | 9 | 12.2 | |
| (range) | (Male: 14-18) | (6.7-11.4) | (8.6-15.5) | (8-10) | (8-14.9) |
| (Female: 12-16) | |||||
| Lactate dehydrogenase, U/L | |||||
| Average | 1107 | 332 | 2693 | 300 | |
| (range) | (230 -460) | (413-2369) | (246-430) | (2250-3137) | (226-385) |
| Bilirubin, mg/dL | |||||
| Average | 1.5 | 0.5 | ND | 0.7 | |
| (range) | (0.20 -1.20) | (1.1-1.9) | (0.2-0.9) | (0.6-0.9) | |
| Creatinine, mg/dL | |||||
| Average | 1.2 | 1.0 | 0.5* | 0.7 | |
| (range) | (0.60 -1.30) | (1.1-1.4) | (0.6-1.2) | (0.6-0.8) | |
| C3, mg/dL | |||||
| Average | 113 | 106 | ND | 87 | |
| (range) | (83 -177) | (78-167) | (67-161) | (72-97) | |
| C4, mg/dL | |||||
| Average | 26 | 22 | ND | 19 | |
| (range) | (15 -45) | (11-59) | (18-28) | (11-25) | |
| VWF antigen, % | |||||
| Average | 162 | 126 | ND | 160 | |
| (range) | (50 -150) | (58-249) | (51-320) | (48-335) | |
| Protease activity, no. of patients | |||||
| Less than 6% | 8 | 4 | 3 | 3 | |
| 6% to 20% | 1 | 4 | 0 | 0 | |
| 21% to 49% | 0 | 0 | 0 | 0 | |
| 50% or more | 0 | 5 | 0 | 1 | |
| Protease inhibitor, no. of patients | |||||
| Present | 7 | 4 | ND | 0 | |
| Absent | 2 | 9 | 4 | ||
| Variable . | Normal range . | Recurrent . | Familial . | ||
|---|---|---|---|---|---|
| Acute (n = 9) . | Remission (n = 13) . | Acute (n = 3) . | Remission (n = 4) . | ||
| Platelets, × 1000/μL | |||||
| Average | 29 | 232 | 38 | 253 | |
| (range) | (150 -400) | (10-71) | (178-399) | (9-34) | (191-352) |
| Hemoglobin, g/dL | |||||
| Average | 9.3 | 13.2 | 9 | 12.2 | |
| (range) | (Male: 14-18) | (6.7-11.4) | (8.6-15.5) | (8-10) | (8-14.9) |
| (Female: 12-16) | |||||
| Lactate dehydrogenase, U/L | |||||
| Average | 1107 | 332 | 2693 | 300 | |
| (range) | (230 -460) | (413-2369) | (246-430) | (2250-3137) | (226-385) |
| Bilirubin, mg/dL | |||||
| Average | 1.5 | 0.5 | ND | 0.7 | |
| (range) | (0.20 -1.20) | (1.1-1.9) | (0.2-0.9) | (0.6-0.9) | |
| Creatinine, mg/dL | |||||
| Average | 1.2 | 1.0 | 0.5* | 0.7 | |
| (range) | (0.60 -1.30) | (1.1-1.4) | (0.6-1.2) | (0.6-0.8) | |
| C3, mg/dL | |||||
| Average | 113 | 106 | ND | 87 | |
| (range) | (83 -177) | (78-167) | (67-161) | (72-97) | |
| C4, mg/dL | |||||
| Average | 26 | 22 | ND | 19 | |
| (range) | (15 -45) | (11-59) | (18-28) | (11-25) | |
| VWF antigen, % | |||||
| Average | 162 | 126 | ND | 160 | |
| (range) | (50 -150) | (58-249) | (51-320) | (48-335) | |
| Protease activity, no. of patients | |||||
| Less than 6% | 8 | 4 | 3 | 3 | |
| 6% to 20% | 1 | 4 | 0 | 0 | |
| 21% to 49% | 0 | 0 | 0 | 0 | |
| 50% or more | 0 | 5 | 0 | 1 | |
| Protease inhibitor, no. of patients | |||||
| Present | 7 | 4 | ND | 0 | |
| Absent | 2 | 9 | 4 | ||
ND indicates not determined.
Data are available on only 1 patient.